Abstract
A high (20%) prevalence of glucose intolerance at 18-years was seen in women from the Pune Maternal Nutrition Study (PMNS) birth cohort. Here, we provide preliminary longitudinal analyses of circulating microRNAs in normal glucose tolerant (NGT@18y, N=10) and glucose intolerant (N=8) women (ADA criteria) at 6-, 12- and 17-years of their age using discovery analysis (OpenArray™ platform). Machine-learning workflows involving Lasso with bootstrapping/leave-one-out cross-validation (LOOCV) identified microRNAs associated with glucose intolerance at 18-years of age. Several microRNAs, including miR-212-3p, miR-30e-3p and miR-638, stratified glucose-intolerant women from NGT at childhood. Our results suggest that circulating microRNAs in childhood could predict pre-diabetes at 18-years of age. Validation of these findings in males and remaining participants from the PMNS birth cohort will provide a unique opportunity to study novel epigenetic mechanisms in the life-course progression of glucose intolerance and enhance current clinical risk prediction of pre-diabetes and progression to type 2 diabetes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Fellowship support from Australian Diabetes Society (Skip Martin Award, 2016) and AISRF EMCR fellowship 2018-19 (Australian Academy of Science) to MVJ is acknowledged. AAH is supported by grants from Juvenile Diabetes Research Foundation (JDRF) Australia T1D Clinical Research Network (JDRF/4-CDA2016-228-MB) and Visiting Professorships (2016-18 and 2019-22) from the Danish Diabetes Academy, funded by the Novo Nordisk Foundation, grant number NNF17SA0031406. WKMW is supported through the Leona M. and Harry B. Helmsley Charitable Trust (Grant 2018PG-T1D009) in collaboration with the JDRF Australian Type 1 Diabetes Clinical Research Network funding (Grant 3-SRA-2019-694-M-B to AAH). PMNS was funded by the Wellcome Trust, UK (038128/Z/93, 059609/Z/99, 079877/Z/06/Z, 098575/B/12/Z and 083460/Z/07/Z), MRC, UK (MR/J000094/1) and Department of Biotechnology, GoI (BT/PR-6870/PID/20/268/2005). Between these grants, the study was funded intramurally (KEMHRC). CSY and AAH were both visiting professors to the Danish Diabetes Academy when these measurements were made.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by village leaders and the KEM Hospital Research Centre Ethics Committee. Parents gave written consent; children under 18 years of age gave written assent, and written consent after reaching 18 years.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
